Mostrar el registro sencillo del ítem

dc.contributor.authorSoriano, Vicente
dc.contributor.authorAguilera, Antonio
dc.contributor.authorBenito, Rafael
dc.contributor.authorGonzalez-Diez, Rocio
dc.contributor.authorMiro, Elisenda
dc.contributor.authorLiendo, Paloma
dc.contributor.authorRodriguez-Diaz, Juan Carlos
dc.contributor.authorCabezas, Teresa
dc.contributor.authorRichart, Alberto
dc.contributor.authorRamos, José Manuel
dc.contributor.authorBarea, Luisa
dc.contributor.authorAlvarez, Carmen
dc.contributor.authorTreviño, Ana
dc.contributor.authorGómez-Gallego, Felix
dc.contributor.authorCorral, Octavio Jorge
dc.contributor.authorde Mendoza, Carmen
dc.date2023
dc.date.accessioned2023-10-30T14:00:45Z
dc.date.available2023-10-30T14:00:45Z
dc.identifier.citationVicente Soriano, Víctor Moreno-Torres, Ana Treviño, Pablo Barreiro, Fernando de Jesus, Octavio Corral, Carmen de Mendoza, Safety considerations in the management of hepatitis C and HIV co-infection, Expert Opinion on Drug Safety, 10.1080/14740338.2023.2206647, (1-10), (2023).es_ES
dc.identifier.issn1478-3223
dc.identifier.urihttps://reunir.unir.net/handle/123456789/15497
dc.description.abstractBackgroundA protective hepatitis B virus (HBV) vaccine has been available for four decades. Universal HBV vaccination of infants is recommended by the WHO since the 1990s. Furthermore, HBV immunization is advised for all adults with high-risk behaviours and no seroprotection. However, HBV vaccine coverage remains globally suboptimal. The advent of new more efficacious trivalent HBV vaccines has renewed the interest in HBV vaccination. At present, the extent of current HBV susceptibility in adults remains unknown in Spain. MethodsHBV serological markers were assessed on a large and representative sample of adults in Spain, including blood donors and individuals belonging to high-risk groups. Serum HBsAg, anti-HBc and anti-HBs were tested in specimens collected during the last couple of years. ResultsFrom 13 859 consecutive adults tested at seven cities across the Spanish geography, overall 166 (1.2%) had positive HBsAg. Past HBV infection was recognized in 14% and prior vaccine immunization in 24%. Unexpectedly, 37% of blood donors and 63% of persons belonging to high-risk groups had no serum HBV markers and therefore were potentially HBV susceptible. ConclusionRoughly 60% of adults living in Spain seem to be HBV susceptible. Waning immunity might be more common than expected. Hence, HBV serological testing should be performed at least once in all adults regardless of risk exposures. HBV vaccine full courses or boosters should be administered to all adults lacking serological evidence of HBV protection.es_ES
dc.language.isoenges_ES
dc.publisherLiver Internationales_ES
dc.relation.ispartofseries;vol. 43, nº 5
dc.relation.urihttps://onlinelibrary.wiley.com/doi/10.1111/liv.15548es_ES
dc.rightsrestrictedAccesses_ES
dc.subjectantibody waninges_ES
dc.subjectdiagnosises_ES
dc.subjecthepatitis Bes_ES
dc.subjectpreventiones_ES
dc.subjectpublic healthes_ES
dc.subjectvaccinees_ES
dc.subjectJCRes_ES
dc.subjectScopuses_ES
dc.titleSusceptibility to hepatitis B virus infection in adults living in Spaines_ES
dc.typeArticulo Revista Indexadaes_ES
reunir.tag~ARIes_ES
dc.identifier.doihttps://doi.org/10.1111/liv.15548


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem